Canada
· Delayed Price · Currency is CAD Eli Lilly and Company Statistics
Total Valuation
Eli Lilly and Company has a market cap or net worth of CAD 993.59 billion. The enterprise value is 1.03 trillion.
| Market Cap | 993.59B |
| Enterprise Value | 1.03T |
Important Dates
The next estimated earnings date is Friday, January 31, 2025.
| Earnings Date | Jan 31, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
| Current Share Class | n/a |
| Shares Outstanding | n/a |
| Shares Change (YoY) | +0.08% |
| Shares Change (QoQ) | +0.09% |
| Owned by Insiders (%) | n/a |
| Owned by Institutions (%) | n/a |
| Float | 898.40M |
Valuation Ratios
The trailing PE ratio is 87.87.
| PE Ratio | 87.87 |
| Forward PE | n/a |
| PS Ratio | n/a |
| PB Ratio | n/a |
| P/TBV Ratio | 380.23 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
The stock's EV/EBITDA ratio is 42.93, with an EV/FCF ratio of 546.12.
| EV / Earnings | 91.33 |
| EV / Sales | 17.58 |
| EV / EBITDA | 42.93 |
| EV / EBIT | 48.23 |
| EV / FCF | 546.12 |
Financial Position
The company has a current ratio of 1.27, with a Debt / Equity ratio of 2.18.
| Current Ratio | 1.27 |
| Quick Ratio | 0.63 |
| Debt / Equity | 2.18 |
| Debt / EBITDA | 1.87 |
| Debt / FCF | 22.31 |
| Interest Coverage | 21.46 |
Financial Efficiency
Return on equity (ROE) is 65.32% and return on invested capital (ROIC) is 24.12%.
| Return on Equity (ROE) | 65.32% |
| Return on Assets (ROA) | 13.95% |
| Return on Capital (ROIC) | 24.12% |
| Revenue Per Employee | 1.28M |
| Profits Per Employee | 262,961 |
| Employee Count | 43,000 |
| Asset Turnover | 0.61 |
| Inventory Turnover | 1.26 |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +30.44% in the last 52 weeks.
| Beta (5Y) | n/a |
| 52-Week Price Change | +30.44% |
| 50-Day Moving Average | 30.58 |
| 200-Day Moving Average | 31.44 |
| Relative Strength Index (RSI) | 39.66 |
| Average Volume (20 Days) | 59,262 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | 1.55 |
Income Statement
In the last 12 months, Eli Lilly and Company had revenue of CAD 55.20 billion and earned 11.31 billion in profits. Earnings per share was 12.50.
| Revenue | 55.20B |
| Gross Profit | 44.66B |
| Operating Income | 20.13B |
| Pretax Income | 13.71B |
| Net Income | 11.31B |
| EBITDA | 22.38B |
| EBIT | 20.13B |
| Earnings Per Share (EPS) | 12.50 |
Balance Sheet
The company has 4.75 billion in cash and 42.19 billion in debt, giving a net cash position of -36.69 billion.
| Cash & Cash Equivalents | 4.75B |
| Total Debt | 42.19B |
| Net Cash | -36.69B |
| Net Cash Per Share | n/a |
| Equity (Book Value) | 19.35B |
| Book Value Per Share | 21.38 |
| Working Capital | 9.11B |
Cash Flow
In the last 12 months, operating cash flow was 8.15 billion and capital expenditures -6.26 billion, giving a free cash flow of 1.89 billion.
| Operating Cash Flow | 8.15B |
| Capital Expenditures | -6.26B |
| Free Cash Flow | 1.89B |
| FCF Per Share | n/a |
Margins
Gross margin is 80.91%, with operating and profit margins of 36.46% and 20.48%.
| Gross Margin | 80.91% |
| Operating Margin | 36.46% |
| Pretax Margin | 24.84% |
| Profit Margin | 20.48% |
| EBITDA Margin | 40.54% |
| EBIT Margin | 36.46% |
| FCF Margin | 3.43% |
Dividends & Yields
Eli Lilly and Company does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | 54.12% |
| Buyback Yield | -0.08% |
| Shareholder Yield | -0.08% |
| Earnings Yield | n/a |
| FCF Yield | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
Eli Lilly and Company has an Altman Z-Score of 8.15.
| Altman Z-Score | 8.15 |
| Piotroski F-Score | n/a |